

Alexis Mathian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058229/publications.pdf>

Version: 2024-02-01

114
papers

8,353
citations

53660

45
h-index

48187

88
g-index

119
all docs

119
docs citations

119
times ranked

13680
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. <i>Immunity</i> , 2009, 30, 899-911.	6.6	1,955
2	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	840
3	IFN- γ Induces Early Lethal Lupus in Preautoimmune (New Zealand Black \times New Zealand White)F1 but Not in BALB/c Mice. <i>Journal of Immunology</i> , 2005, 174, 2499-2506.	0.4	248
4	Pathogenesis of Takayasu's arteritis: A 2011 update. <i>Autoimmunity Reviews</i> , 2011, 11, 61-67.	2.5	223
5	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 837-839.	0.5	208
6	Microbial ecology perturbation in human IgA deficiency. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	206
7	IFN- γ kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5294-5299.	3.3	205
8	Mevalonate Kinase Deficiency: A Survey of 50 Patients. <i>Pediatrics</i> , 2011, 128, e152-e159.	1.0	195
9	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	1.1	174
10	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. <i>Autoimmunity Reviews</i> , 2014, 13, 281-291.	2.5	166
11	Prevalence and severity of malnutrition in hospitalized COVID-19 patients. <i>Clinical Nutrition ESPEN</i> , 2020, 40, 214-219.	0.5	139
12	Deficiency of Type I IFN Receptor in Lupus-Prone New Zealand Mixed 2328 Mice Decreases Dendritic Cell Numbers and Activation and Protects from Disease. <i>Journal of Immunology</i> , 2009, 183, 6021-6029.	0.4	122
13	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2015, 14, 192-200.	2.5	118
14	FoxP3+ Regulatory T Cells Suppress Early Stages of Granuloma Formation but Have Little Impact on Sarcoidosis Lesions. <i>American Journal of Pathology</i> , 2009, 174, 497-508.	1.9	116
15	Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon- γ production in patients with active disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 1698-1706.	6.7	116
16	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.5	112
17	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	2.1	111
18	Pathogenesis of relapsing polychondritis: A 2013 update. <i>Autoimmunity Reviews</i> , 2014, 13, 90-95.	2.5	110

#	ARTICLE	IF	CITATIONS
19	Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. <i>Autoimmunity Reviews</i> , 2014, 13, 1082-1089.	2.5	106
20	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. <i>Autoimmunity Reviews</i> , 2017, 16, 743-749.	2.5	101
21	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	1.4	101
22	Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 339-346.	0.5	93
23	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	2.0	91
24	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1227-1234.	0.5	90
25	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. <i>Journal of Neurology</i> , 2017, 264, 891-897.	1.8	90
26	Systemic IFN γ drives kidney nephritis in B6.Sle123 mice. <i>European Journal of Immunology</i> , 2008, 38, 1948-1960.	1.6	89
27	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1575-1585.e4.	1.5	86
28	Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. <i>British Journal of Haematology</i> , 2022, 196, 969-974.	1.2	85
29	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. <i>Autoimmunity Reviews</i> , 2014, 13, 730-735.	2.5	79
30	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 316-333.	1.4	79
31	Late-Onset Systemic Lupus Erythematosus. <i>Drugs and Aging</i> , 2012, 29, 181-189.	1.3	78
32	Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. <i>Chest</i> , 2021, 159, 657-662.	0.4	78
33	B Cell and BAFF Dependence of IFN γ Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice. <i>Journal of Immunology</i> , 2011, 186, 4984-4993.	0.4	77
34	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3179-3189.	1.8	72
35	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	2.5	71
36	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.4	67

#	ARTICLE	IF	CITATIONS
37	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.5	61
38	Ultrasensitive serum interferon- γ quantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1669-1676.	0.5	59
39	Interferon- γ induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB–NZW)F1 mice but not in BALB/c mice. <i>European Journal of Immunology</i> , 2011, 41, 863-872.	1.6	58
40	Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects. <i>Drugs</i> , 2015, 75, 835-846.	4.9	58
41	Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 83-89.	1.6	57
42	IFN- γ and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18995-19000.	3.3	52
43	Type-I interferons and systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2006, 5, 554-562.	2.5	51
44	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon- γ . <i>Arthritis and Rheumatology</i> , 2019, 71, 756-765.	2.9	51
45	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 377-384.	2.5	49
46	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	1.5	47
47	Relapsing polychondritis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000788.	1.8	43
48	Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3502-3511.	6.7	42
49	Active immunisation of human interferon γ transgenic mice with a human interferon γ Kinoid induces antibodies that neutralise interferon γ in sera from patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1138-1143.	0.5	41
50	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1209-1215.	1.0	41
51	Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. <i>Arthritis and Rheumatism</i> , 2011, 63, 1136-1140.	6.7	39
52	The histiocytosis Erdheim–Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1033-1042.	1.3	38
53	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212705.	0.5	38
54	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0143689.	1.1	37

#	ARTICLE	IF	CITATIONS
55	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. <i>Nephrology Dialysis Transplantation</i> , 2017, 33, 1579-1590.	0.4	37
56	Mediation of nonerosive arthritis in a mouse model of lupus by interferon- γ -stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1127-1137.	6.7	36
57	Ultraviolet light converts propranolol, a nonselective β_2 -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , 2015, 45, 3174-3187.	1.6	36
58	Contact dermatitis due to ultrasound gel: A case report and published work review. <i>Journal of Dermatology</i> , 2016, 43, 318-320.	0.6	32
59	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	2.5	32
60	Response to: "Correspondence on "Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine" by Nikpour et al". <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e34-e34.	0.5	29
61	Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 1218-1226.	1.8	23
62	Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. <i>Nutrients</i> , 2021, 13, 2276.	1.7	21
63	Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. <i>Neurology</i> , 2002, 59, 1468-1469.	1.5	20
64	COVID-19-associated collapsing glomerulopathy: a report of two cases and literature review. <i>Internal Medicine Journal</i> , 2020, 50, 1551-1558.	0.5	19
65	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. <i>Journal of Neurology</i> , 2019, 266, 1073-1078.	1.8	18
66	Lupus and vaccinations. <i>Current Opinion in Rheumatology</i> , 2018, 30, 465-470.	2.0	14
67	Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1171-1174.	0.6	14
68	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 474-475.	0.5	12
69	In-Hospital Mortality-Associated Factors in Patients With Thrombotic Antiphospholipid Syndrome Requiring ICU Admission. <i>Chest</i> , 2020, 157, 1158-1166.	0.4	12
70	AA amyloidosis is an emerging cause of nephropathy in obese patients. <i>European Journal of Internal Medicine</i> , 2017, 39, e18-e20.	1.0	11
71	Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1539-1540.	1.5	11
72	Serum interferon- λ levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 901-903.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	1.0	10
74	Correspondence on Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e241-e241.	0.5	10
75	TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1 ^β positive cancer-associated dermatomyositis. <i>Rheumatology</i> , 2021, 60, 5863-5867.	0.9	10
76	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. <i>Frontiers in Immunology</i> , 2022, 13, 790334.	2.2	10
77	Successful Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock Due to the Catastrophic Antiphospholipid Syndrome. <i>Annals of Internal Medicine</i> , 2010, 153, 487.	2.0	8
78	Iron deficiency, an unusual cause of thrombocytopenia: results from a multicenter retrospective case-controlled study. <i>Annals of Hematology</i> , 2019, 98, 2299-2302.	0.8	8
79	Transvenous Renal Biopsy of Critically Ill Patients: Safety and Diagnostic Yield. <i>Critical Care Medicine</i> , 2019, 47, 386-392.	0.4	8
80	Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e148-e148.	0.5	8
81	Response to Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e217-e217.	0.5	8
82	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. <i>Kidney International Reports</i> , 2021, 6, 526-528.	0.4	8
83	Panitumumab-Induced Immune Complex Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 320-321.	2.1	7
84	CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. <i>Journal of Autoimmunity</i> , 2019, 103, 102292.	3.0	7
85	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1721-1729.	0.4	7
86	Acute posterior multifocal placoid pigment epitheliopathy as the initial manifestation of sarcoidosis. <i>Journal of Ophthalmic and Vision Research</i> , 2011, 6, 338-43.	0.7	7
87	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , 2019, 39, 171-181.	2.0	6
88	Coronary artery disease in systemic lupus: A case-controlled angiographic study. <i>Autoimmunity Reviews</i> , 2020, 19, 102427.	2.5	5
89	Severe Viral Myopericarditis With Autoantibodies Directed Against RNA Polymerase III. <i>Annals of Internal Medicine</i> , 2020, 172, 502.	2.0	5
90	Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. <i>European Journal of Cancer</i> , 2021, 149, 34-36.	1.3	5

#	ARTICLE	IF	CITATIONS
91	Clarkson's Disease Episode or Secondary Systemic Capillary Leak-Syndrome. <i>Chest</i> , 2021, 159, 441.	0.4	5
92	Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. <i>Neuromuscular Disorders</i> , 2018, 28, 334-338.	0.3	3
93	Handling shock in idiopathic systemic capillary leak syndrome (Clarkson's disease): less is more comment. <i>Internal and Emergency Medicine</i> , 2020, 15, 347-348.	1.0	3
94	Reducing lupus flares: should we be more careful about stopping glucocorticoids?. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 539-542.	1.3	3
95	Response to: "Implications of SARS-CoV-2 infection for patients with rheumatic disease" by Lin et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e153-e153.	0.5	2
96	Response to "Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic" by Chuah et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e145-e145.	0.5	2
97	Systemic chloroquine intoxication: a hint from the peripheral blood smear. <i>American Journal of Hematology</i> , 2020, 95, 873-875.	2.0	2
98	Response to: "Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak" by Holubar et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e57-e57.	0.5	2
99	Response to: "Presence of anti-phospholipid antibodies in COVID-19: a case series study" by Amezcua-Guerra et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e74-e74.	0.5	2
100	Response to: "Are patients with systemic lupus erythematosus at increased risk for COVID-19?" by Favalli et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e26-e26.	0.5	2
101	Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry. <i>Blood</i> , 2021, 138, 3689-3689.	0.6	2
102	Atypical ocular manifestation of primary varicella zoster virus infection as the first manifestation of AIDS. <i>Aids</i> , 2016, 30, 674-676.	1.0	1
103	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 214, 201-203.	0.5	0
104	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 197-197.	2.9	0
105	Response. <i>Chest</i> , 2020, 158, 429-430.	0.4	0
106	Response to: "Withdrawal of low-dose prednisone in inactive SLE patients: is there another alternative?" by Sabio. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e58-e58.	0.5	0
107	Response to: "Glucocorticoid withdrawal in lupus: to do or not to do?" by Acharya. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e45-e45.	0.5	0
108	Response to: "Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial" by Mousavi and Taherifard. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e47-e47.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Response to: "Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey" by PIAI et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e53-e53.	0.5	0
110	Response to: "Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus" by Kondo et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e78-e78.	0.5	0
111	Response to: "COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine" by Teh et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e70-e70.	0.5	0
112	Response to: "Patients with lupus with COVID-19: University of Michigan experience" by Wallace et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e36-e36.	0.5	0
113	Response to: "Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India" by Goyal et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e72-e72.	0.5	0
114	Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive-Interstitial Lung Disease. <i>Chest</i> , 2021, 160, e680-e681.	0.4	0